Avalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics appointed Ron Philip to its Board of Directors, adding over 30 years of biopharmaceutical leadership experience including multiple billion-dollar exits. Mr. Philip previously served as CEO of Orbital Therapeutics during its acquisition by Bristol Myers Squibb and as CEO of Spark Therapeutics during its acquisition by Roche.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.